Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on April 28, 2025
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
GlobeNewswire
·
April 28, 2025
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will …
BriaCell Therapeutics Announces Closing of $13.8 million Public Offering
GlobeNewswire
·
April 28, 2025
PHILADELPHIA and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to …
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
GlobeNewswire
·
April 28, 2025
SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced poster presentations …
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
GlobeNewswire
·
April 28, 2025
- FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Preclinical synergistic anti-tumor activity of FHD-909 in combination with pembrolizumab and KRAS …
LifeMD to Report First Quarter 2025 Financial Results on May 6
GlobeNewswire
·
April 28, 2025
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial …
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
GlobeNewswire
·
April 28, 2025
SINGAPORE, April 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel …
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
GlobeNewswire
·
April 28, 2025
BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that a presentation …
Kane Biotech Announces Fourth Quarter and Full Year 2024 Financial Results, Narrows Strategic Focus and Makes Leadership Change
GlobeNewswire
·
April 28, 2025
WINNIPEG, Manitoba, April 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announced its fourth quarter and full year 2024 financial results. Fourth Quarter 2024 Financial Highlights ( …
Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025
GlobeNewswire
·
April 28, 2025
BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced multiple presentations …
Solésence To Report First Quarter 2025 Financial Results and Host a Conference Call
GlobeNewswire
·
April 28, 2025
ROMEOVILLE, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Romeoville, Ill., April 28, 2025 – Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will …
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer
GlobeNewswire
·
April 28, 2025
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial …
Jack Herer Enters Global Pharma Market Through Partnership with SOMAÍ
EIN Presswire
·
April 28, 2025
LISBON, PORTUGAL, April 28, 2025 /EINPresswire.com/ -- The Jack Herer Brand, an iconic U.S.-based cannabis company, has announced a strategic partnership with SOMAÍ, a leading EU-GMP-certified vertically integrated Multi-Country Operator (MCO) …
CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting
GlobeNewswire
·
April 28, 2025
SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced new preclinical data in collaboration with Moderna on an mRNA …
Cronos Group Inc. to Hold Virtual 2025 Annual Meeting of Shareholders
GlobeNewswire
·
April 28, 2025
TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2025 Annual Meeting of Shareholders on Friday, June 20, 2025, at 11:00 a.m. ET. Cronos will be conducting the meeting in a …
Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs
GlobeNewswire
·
April 28, 2025
Nurix’s DEL-AI platform uses a first-in-class DEL Foundation Model trained on the Company’s proprietary DNA encoded library data Nurix’s DEL Foundation Model can accurately predict novel binders to therapeutically relevant targets, including many targets …
Dr Amber Hartman Scholz selected for Steering Committee of Multilateral Mechanism on Digital Sequence Information/UN CBD
EIN Presswire
·
April 28, 2025
BRAUNSCHWEIG, GERMANY, April 28, 2025 /EINPresswire.com/ -- Dr. Amber Hartman Scholz, Head of the Department of Science Policy and Internationalization at the Leibniz Institute DSMZ-German Culture Collection of Microorganisms and Cell Cultures GmbH, has …
Frontier Medicines Unveils New Preclinical Data for FMC-220, a First-in-Class Covalent p53 Y220C Activator, at AACR 2025
GlobeNewswire
·
April 28, 2025
Sustained reactivation of mutant p53 drives durable anti-tumor activity across models, including KRAS co-mutant tumors FMC-220 selectively stabilizes p53 Y220C at lower doses, overcoming key limitations of non-covalent approaches Addresses a defined …
UAE Positioned to Lead Global Longevity Movement as Nordic Laboratories Conference Takes Place in Dubai
EIN Presswire
·
April 28, 2025
As global focus turns to healthspan optimisation, a new wave of UAE-based practitioners is transforming how we age - inside and out. DUBAI, UNITED ARAB EMIRATES, April 28, 2025 /EINPresswire.com/ -- The UAE is rapidly establishing itself as a powerhouse …
Helping Kids Brush Their Teeth: HelloNation Spotlights Dr. Andrew Beuttenmuller of Watertown Pediatric Dentistry And How He Gets Kids Excited About Oral Health
GlobeNewswire
·
April 28, 2025
WATERTOWN, N.Y., April 28, 2025 (GLOBE NEWSWIRE) -- Making dental hygiene fun is a crucial step in helping children build positive associations with oral care. This is a perspective emphasized by Dr. Andrew Beuttenmuller of Watertown Pediatric Dentistry, …
Supra Keto ACV Gummies: Best Gummies for Weight Loss 2025 - (Keto BHB + Keto Plus)
GlobeNewswire
·
April 28, 2025
New York, April 28, 2025 (GLOBE NEWSWIRE) -- Within the weight loss supplement industry, Supra Keto BHB + ACV Gummies are revolutionary, employing two of the best fat-burning compounds: Beta-Hydroxybutyrate (BHB) and Apple Cider Vinegar (ACV). The goal of …